Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Cited by (1,000)

Items 201–300 of 1,000

1. Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
   Amrita Y. Krishnan, Matthew Genyeh Mei, Can‐Lan Sun, Sandra H. Thomas, Jennifer Berano Teh, Tongjun Kang, Myo Htut, George Somlo, Firoozeh Sahebi, Stephen J. Forman et al. · 2012 · Transplantation and Cellular Therapy
2. Minimal Residual Disease in Multiple Myeloma
   Nikhil C. Munshi, Kenneth Carl Anderson · 2013 · Journal of Clinical Oncology
3. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
   Syed Mohammad Ali Kazmi, Maliha Nusrat, Hilal Gunaydin, Amanda Megan Cornelison, Nina D. Shah, Partow Kebriaei, Yago L. Nieto, Simrit Parmar, Uday Popat, Betül Oran et al. · 2015 · Clinical Lymphoma Myeloma & Leukemia
4. How I treat the young patient with multiple myeloma
   Sara Gandolfi, Claudia Paba Prada, Paul Gerard Guy Richardson · 2018 · Blood
5. Role of Stem Cell Transplantation in Multiple Myeloma
   Srinivas S. Devarakonda, Yvonne Adeduni Efebera, Nidhi Sharma · 2021 · Cancers
6. Recent advances in hematopoietic stem cell transplantation
   Maxim N. Norkin, John R. Wingard · 2017 · F1000Research
7. Targeting the Microenvironment for Treating Multiple Myeloma
   Peter Neumeister, Eduard Schulz, Katrin Pansy, Marta Szmyra, Alexander J. A. Deutsch · 2022 · International Journal of Molecular Sciences
8. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
   Saad Z. Usmani, Jeffrey R. Sawyer, Adam Rosenthal, Michele Cottler‐Fox, Joshua Epstein, Shmuel Yaccoby, Rachael Sexton, Antje Hoering, Zeba N. Singh, Christoph Johann Heuck et al. · 2013 · Blood
9. Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma
   Daniel J. Royston, Qi Gao, Nghia Nguyen, Peter George Maslak, Ahmet Doǧan, Mikhail Roshal · 2016 · American Journal of Clinical Pathology
10. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma
    Alessandro Stecco, Francesco Buemi, Antoine Iannessi, Alessandro Carriero, Andrea Gallamini · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
11. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Shijia Zhang, Amit A. Kulkarni, Beibei Xu, Haitao Chu, Taxiarchis Kourelis, Ronald S. Go, Michael L. Wang, Veronika Bachanová, Yucai Wang · 2020 · Blood Cancer Journal
12. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
    Pieter Sonneveld, Meletios Athanasios Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester et al. · 2021 · Journal of Clinical Oncology
13. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
    Ola Landgren, Roger G. Owen · 2015 · Cytometry Part B Clinical Cytometry
14. Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis
    Emma Catherine Scott, Parameswaran Hari, Manish R. Sharma, Jennifer G. Le‐Rademacher, Jiaxing Huang, Dan T. Vogl, Muneer Hyder Abidi, Amer Beitinjaneh, Henry C.H. Fung, Siddhartha Ganguly et al. · 2016 · Transplantation and Cellular Therapy
15. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Murielle Roussel, Benjamin Hébraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Anne‐Marie Stoppa, Margaret Macro, Martine Escoffre‐Barbe, Bertrand Arnulf, Karim Belhadj et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
16. Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis
    on behalf of Deutsche Studiengruppe Multiples Myelom, Stefan Tobias Knop, Monika Martha Engelhardt, Peter Liebisch, Christoph Meisner, Ernst Holler, Bernd Metzner, D. Peest, Martin Kaufmann, Donald Werner Bunjes et al. · 2019 · Leukemia
17. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
    Catarina Maia, Noemí Puig, María‐Teresa Cedena, Ibai Goicoechea, Rafael Valdés‐Mas, Iria Vázquez, Carmen Chillón, Paula Aguirre‐Ruiz, Sarai Sarvide, Francisco Javier Gracia-Aznárez et al. · 2020 · Blood
18. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
    Ria, Roberto, Melaccio, Assunta, Racanelli, Vito, Vacca, Angelo · 2020 · Journal of Clinical Medicine
19. Genome Instability in Multiple Myeloma: Facts and Factors
    Anna Yu. Aksenova, Anna S. Zhuk, Artem G. Lada, Irina V. Zotova, Elena Igorevna Stepchenkova, Ivan Ivanovich Kostroma, Sergey V. Gritsaev, Youri I. Pavlov · 2021 · Cancers
20. Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents
    Anas Ramadan Kotb, Dina A. Bakhotmah, Abdallah E. Abdallah, Hazem Elkady, Mohammed S. Taghour, Ibrahim H. Eissa, Mohamed Ayman El‐Zahabi · 2022 · RSC Advances
21. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
    Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Μαρία Ρούσσου, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Maria Aslani Gkotzamanidou, Nikolaos Kanellias, Efstathios D. Manios et al. · 2013 · Leukemia
22. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
    Robert Zygmunt Orlowski · 2013 · Seminars in Oncology
23. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
    Adriana Rossi, Tomer Martin Mark, David S. Jayabalan, Paul J. Christos, Faiza Zafar, Karen A. Pekle, Roger Niles Pearse, Selina Chen‐Kiang, Morton Coleman, Rubén Niesvizky · 2013 · Blood
24. Emerging Stem Cell Therapies: Treatment, Safety, and Biology
    Joel Sng, Thomas Lufkin · 2012 · Stem Cells International
25. ESRD due to Multiple Myeloma in the United States, 2001–2010
    Scott A. Reule, Donal J. Sexton, Craig A. Solid, Shu‐Cheng Chen, Robert N. Foley · 2015 · Journal of the American Society of Nephrology
26. Integration of Novel Agents into the Care of Patients with Multiple Myeloma
    Robert Zygmunt Orlowski, Sagar Lonial · 2016 · Clinical Cancer Research
27. Quality of life in multiple myeloma: considerations and recommendations
    Samantha Seitzler, Elizabeth Finley-Oliver, Christine Simonelli, Rachid Baz · 2019 · Expert Review of Hematology
28. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
    Geoffrey L. Uy, Luciano J. Costa, Parameswaran Hari, M-J Zhang, J-X Huang, Kenneth Carl Anderson, Christopher Bredeson, Natalie S. Callander, Robert Frank Cornell, M A D Perez et al. · 2015 · Bone Marrow Transplantation
29. The evolution of stem-cell transplantation in multiple myeloma
    Sarakshi Mahajan, Nidhi Tandon, Shaji Kunnathu Kumar · 2018 · Therapeutic Advances in Hematology
30. Hard-Wired Bias
    Vinay K. Prasad, Vance W. Berger · 2015 · Mayo Clinic Proceedings
31. Lenalidomide for the treatment of relapsed and refractory multiple myeloma
    Güllü Görgün, Niels W.C.J. van de Donk, Richard W.J. Groen, Jana Jakubı́ková, Constantine S. Mitsiades, Teru Hideshima, Paul Gerard Guy Richardson, Nijhof, Raymakers, Henk M. Lokhorst et al. · 2012 · Cancer Management and Research
32. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
    Rafael Alonso, María‐Teresa Cedena, Sandy Wai Kuan Wong, Nina D. Shah, Rafael Ríos, Jose Maria Moraleda, Javier López‐Jiménez, Cristina García, Natasha Bahri, Antonio Valeri et al. · 2020 · Blood Advances
33. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
    Binod Dhakal, Nina D. Shah, Ankit J. Kansagra, Ambuj Kumar, Sagar Lonial, Alfred L. Garfall, Andrew J. Cowan, Bishesh Sharma Poudyal, Caitlin L. Costello, Francesca Gay et al. · 2022 · Transplantation and Cellular Therapy
34. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
    Brittany Knick Ragon, Mithun Vinod Shah, Anita D’Souza, Noel Estrada‐Merly, Lohith Gowda, Gemlyn George, Marcos J. G. De Lima, Shahrukh Khurshid Hashmi, Mohamed A. Kharfan‐Dabaja, Navneet S. Majhail et al. · 2023 · Blood Advances
35. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
    N. Chen, Claudia Kasserra, Josephine F. Reyes, L. Liu, Henry S. H. Lau · 2012 · Cancer Chemotherapy and Pharmacology
36. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
    S. Vincent Rajkumar · 2012 · Hematology
37. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
    Hiroyuki Takamatsu · 2017 · Journal of Clinical Medicine
38. Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
    Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Alessandro Fiorentini, Attilio Olivieri, Massimo Offidani · 2022 · Cells
39. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
    Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Cristina Gasparetto, KATHLEEN E. TOOMEY, James W. Hardin, Lynne I. Wagner, Amit Agarwal et al. · 2018 · Blood Advances
40. Staging and prognostication of multiple myeloma
    Rafaël Fonseca, Jorge Monge, Meletios Athanasios Dimopoulos · 2014 · Expert Review of Hematology
41. Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation
    Christopher Simon Hourigan, Philip L. McCarthy, Marcos J. G. De Lima · 2013 · Transplantation and Cellular Therapy
42. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial
    Sergio Giralt, Luciano J. Costa, David G. Maloney, Amrita Y. Krishnan, Mingwei Fei, Joseph H. Antin, Claudio G. Brunstein, Nancy L. Geller, Stacey Ann Goodman, Parameswaran Hari et al. · 2019 · Transplantation and Cellular Therapy
43. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
    Graham Hunter Jackson, Faith E. Davies, Charlotte Pawlyn, David Allan Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R. Jones, Bhuvan Kishore, Mamta Krishnan Garg et al. · 2020 · Haematologica
44. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis
    Sharath Rama, Chong Hyun Suh, Kyung Won Kim, Jared Durieux, Nikhil H. Ramaiya, Sree Harsha Tirumani · 2021 · American Journal of Roentgenology
45. Lenalidomide and secondary acute lymphoblastic leukemia: a case series
    Marisela Tan, Richard Fong, Mimi Lo, Rebecca Young · 2015 · Hematological Oncology
46. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma
    Xin Shelley Wang, Qiuling Shi, Loretta A. Williams, Nina D. Shah, Tito R. Mendoza, Evan N. Cohen, James Mwikya Reuben, Charles S. Cleeland, Robert Zygmunt Orlowski · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
47. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
    Jacob P. Laubach, CE Paba Prada, Paul Gerard Guy Richardson, DL Longo · 2016 · Clinical Pharmacology & Therapeutics
48. Posttransplant maintenance therapy in multiple myeloma: the changing landscape
    Salyka M. Sengsayadeth, Florent Malard, Bipin N. Savani, Laurent Garderet, Mohamad Mohty · 2017 · Blood Cancer Journal
49. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
    Asher Alban Chanan-Khan, Andrey Yu. Zaritskey, Miklós Egyed, Samuel Vokurka, С. В. Семочкин, Anna Schuh, Jeannine Kassis, David Simpson, Jennie Zhang, Brendan Purse et al. · 2017 · The Lancet Haematology
50. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis
    Ankur Varma, Dawen Sui, Denái R. Milton, Guilin Tang, Neeraj Saini, Omar Hasan, Akash Mukherjee, Jacinth Joy Joseph, Qaiser Bashir, Gabriela Rondón et al. · 2019 · Transplantation and Cellular Therapy
51. Multiple myeloma
    Л. П. Менделеева, Ol’ga Mikhailovna Votyakova, Irina Germanovna Rekhtina, Evgenii A. Osmanov, Irina Vladimirovna Poddubnaya, Л. Ю. Гривцова, Natalia A. Falaleeva, В В Байков, Alla Mikhailovna Kovrigina, Aleksei A. Nevol’skikh et al. · 2021 · Journal of Modern Oncology
52. CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
    Joanna Barankiewicz, Aleksander Salomon‐Perzyński, Irena Misiewicz-Krzemińska, Ewa Lech‐Marańda · 2022 · Cancers
53. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
    Massimo Vincenzo Martino, Mauro Montanari, Felicetto Ferrara, Fabio Ciceri, Ilaria Scortechini, Salvatore Palmieri, Sarah Marktel, Michele Cimminiello, Giuseppe Messina, Giuseppe Irrera et al. · 2014 · Transplantation and Cellular Therapy
54. Lenalidomide in Myeloma — A High-Maintenance Friend
    Ashraf Z. Badros · 2012 · New England Journal of Medicine
55. Novel agents and new therapeutic approaches for treatment of multiple myeloma
    Roberto Ria · 2014 · World Journal of Methodology
56. Multiple myeloma maintenance therapy: A review of the pharmacologic treatment
    Brandon R. Shank, Victoria T. Brown, Rowena N Schwartz · 2014 · Journal of Oncology Pharmacy Practice
57. Current Therapeutic Strategy for Multiple Myeloma
    Kenshi Suzuki · 2013 · Japanese Journal of Clinical Oncology
58. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
    Dharshan Sivaraj, Michael M. Green, Zhiguo Li, Anthony Derek Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn Douglas Long, Mitchell E. Horwitz, Richard D. Lopez, Keith M. Sullivan et al. · 2016 · Transplantation and Cellular Therapy
59. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
    Shahzad Raza, Rachael Ann Safyan, Evan Rosenbaum P. E, Chip A. Bowman, Suzanne Lentzsch · 2016 · Therapeutic Advances in Hematology
60. Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
    Paul Gerard Guy Richardson, Craig C. Hofmeister, Cara Ann Rosenbaum, Myo Htut, David H. Vesole, Jesús G. Berdeja, Michaela Liedtke, Ajai Chari, Stephen Douglas Smith, Daniel J. Lebovic et al. · 2018 · British Journal of Haematology
61. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
    Marc‐Andrea Baertsch, Elias Karl Mai, Thomas Hielscher, Uta Bertsch, Hans Jürgen Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben et al. · 2021 · Blood Cancer Journal
62. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
    Fabian M Bock, Gary G. Lu, Samer Ali Srour, Sameh R. Gaballa, Heather Yan Lin, Veerabhadran Baladandayuthapani, Medhavi Honhar, Maximilian Stich, Nina D. Shah, Qaiser Bashir et al. · 2016 · Transplantation and Cellular Therapy
63. Update on second primary malignancies in multiple myeloma: a focused review
    Ola Landgren, Sham Mailankody · 2014 · Leukemia
64. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Geetika Srivastava, Vishal Rana, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Angela A. Dispenzieri, Morie Abraham Gertz, David Dingli, Steven R. Zeldenrust, Stephen J. Russell et al. · 2013 · Leukemia
65. Have drug combinations supplanted stem cell transplantation in myeloma?
    Antonio Pierangelo Palumbo, Federica Cavallo · 2012 · Blood
66. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
    Christian Straka, Peter Liebisch, Hans Jürgen Salwender, Burkhard Hennemann, Bernd Metzner, Stefan Tobias Knop, Sigrid Adler-Reichel, Christian Gerecke, Hannes Wandt, Martin Bentz et al. · 2016 · Haematologica
67. The role of maintenance therapy in multiple myeloma
    Brea C. Lipe, Rachel R. Vukas, Joseph R Mikhael · 2016 · Blood Cancer Journal
68. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
    Rajshekhar Chakraborty, Eli Muchtar, Shaji Kunnathu Kumar, Francis K. Buadi, David Dingli, Angela A. Dispenzieri, Suzanne R. Hayman, W J Hogan, Prashant Kapoor, Martha Q. Lacy et al. · 2017 · Leukemia
69. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
    Paul Gerard Guy Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth Carl Anderson · 2014 · Hematology
70. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
    Massimo Vincenzo Martino, Giovanni Luigi Tripepi, G Messina, Iolanda Donatella Vincelli, Giuseppe Console, Anna Grazia Recchia, Massimo Gentile, Stefano Molica, Fortunato Morabito · 2016 · Bone Marrow Transplantation
71. Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality
    Luciano J. Costa, Kelly Nicole Godby, Saurabh Chhabra, Robert Frank Cornell, Parameswaran Hari, Smita Bhatia · 2018 · British Journal of Haematology
72. The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma
    Patrick Alan Hagen, Patrick J. Stiff · 2018 · Transplantation and Cellular Therapy
73. Current approaches to management of high‐risk multiple myeloma
    Sarah Goldman‐Mazur, Shaji Kunnathu Kumar · 2021 · American Journal of Hematology
74. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
    Mohamad Mohty, Paul Gerard Guy Richardson, Philip L. McCarthy, Michel Attal · 2015 · Bone Marrow Transplantation
75. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point
    Meletios Athanasios Dimopoulos, Maria Teresa Petrucci, Robin Foà, J. Catalano, Martin H. Kropff, Evangelos Terpos, Jingshan Zhang, Ludger Grote, Christian J. Jacques, A. Palumbo · 2015 · Haematologica
76. Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma
    Kamal Kant Singh Abbi, Junting Zheng, Sean M. Devlin, Sergio Giralt, Heather Jolie Landau · 2014 · Transplantation and Cellular Therapy
77. Association between complete response and outcomes in transplant‐eligible myeloma patients in the era of novel agents
    Helgi J. Van de Velde, Anil Londhe, Ö. Ataman, Helen L. Johns, Stephen Hill, Emma Landers, Jesse A. Berlin · 2016 · European Journal Of Haematology
78. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
    Ghulam Rehman Mohyuddin, Kelly Koehn, Leyla Osman Shune, Muhammad Aziz, Al-Ola A. Abdallah, Brian Lee McClune, Siddhartha Ganguly, Joseph P. McGuirk, Suman Kambhampati · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
79. Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
    Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan, Manoj Kumar Pandey · 2023 · Pharmaceuticals
80. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy
    Andrew J. Cowan, Philip A. Stevenson, Edward N. Libby, Pamela Sue Becker, David Glen Coffey, Damian J. Green, Teresa S. Hyun, Jonathan R. Fromm, Ajay K. Gopal, Leona Holmberg · 2018 · Transplantation and Cellular Therapy
81. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma
    Mukul Aggarwal, Narendra Agrawal, Neha Yadav, Priyanka Verma, Rayaz Ahmed, Pallavi Mehta, Jyotsna Kapoor, Dinesh Bhurani · 2018 · Annals of Hematology
82. Expanding role of lenalidomide in hematologic malignancies
    Nilanjan Ghosh, Michael Richard Grunwald, Omotayo O. Fasan, Manisha Bhutani · 2015 · Cancer Management and Research
83. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients
    Philip L. McCarthy, Theresa Hahn · 2013 · Hematology
84. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
    Jason B. Brayer, Rachid Baz · 2017 · Therapeutic Advances in Hematology
85. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries
    Vânia Hungria, Jae Hoon Lee, Ângelo Maiolino, Edvan de Queiroz Crusoé, Gracia Martınez, Rosane Bittencourt, Gislaine Oliveira Duarte, Dorotea Beatriz Eugenia Fantl, Juan Ramón Navarro, Guillermo F. Conte et al. · 2019 · Annals of Hematology
86. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
    Robert Frank Cornell, Samuel Zachary Goldhaber, Brian G. Engelhardt, Javid J. Moslehi, Madan Jagasia, Daryl Patton, Shelton Lacy Harrell, Robert Hall, Houston Wyatt, Greg Piazza · 2019 · Frontiers in Oncology
87. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Anita D’Souza, Parameswaran Hari, Marcelo C. Pasquini, Thomas Braun, Bryon Johnson, Steven K. Lundy, Daniel R. Couriel, Mehdi Hamadani, John Martin Magenau, Binod Dhakal et al. · 2019 · Transplantation and Cellular Therapy
88. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
    Hans Jürgen Salwender, Uta Bertsch, Katja Christina Weisel, Jan Dürig, Christina Kunz, Axel Benner, Igor Wolfgang Blau, Marc Steffen Raab, Jens Hillengaß, Dirk Hose et al. · 2019 · BMC Cancer
89. Immunomodulatory drugs in the treatment of multiple myeloma
    Yu Abe, Tadao Ishida · 2019 · Japanese Journal of Clinical Oncology
90. How I treat frontline transplantation-eligible multiple myeloma
    Aurore Perrot · 2021 · Blood
91. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
    Luca Bertamini, Giuseppe Bertuglia, Stefania Oliva · 2022 · Frontiers in Oncology
92. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
    Carolina Terragna, Daniel Remondini, Marina Martello, Elena Zamagni, Lucia Pantani, Francesca F. Patriarca, Annalisa Pezzi, Giuseppe Levi, Massimo Offidani, Ilaria Proserpio et al. · 2015 · Oncotarget
93. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance
    Jorge Julio Castillo, Morie Abraham Gertz · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
94. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Sarah A. Holstein, Vera Jean Suman, Philip L. McCarthy · 2019 · Current Hematologic Malignancy Reports
95. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Maximilian Merz, Tobias Nicolaas Dechow, Mithun Scheytt, Christian Schmidt, Bjoern Hackanson, Stefan Tobias Knop · 2020 · Annals of Hematology
96. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
    Rodrigo Fonseca, Mariano Arribas, Julia Erin Wiedmeier, Yael N. Kusne, Miguel González Vélez, Heidi Kosiorek, Richard J Butterfield, Ilan Richard Kirsch, Joseph R Mikhael, A. Keith Stewart et al. · 2023 · Blood Cancer Journal
97. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
    Kenneth H. Shain, Jianguo Tao · 2013 · Oncogene
98. A review of the venous thrombotic issues associated with multiple myeloma
    Despina Fotiou, Grigoris Gerotziafas, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos · 2016 · Expert Review of Hematology
99. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Yahiya Y. Syed · 2017 · Drugs
100. Fixed duration vs continuous therapy in multiple myeloma
     Heinz Ludwig, Niklas Zojer · 2017 · Hematology